Invesco Pharmaceuticals ETF (PJP)

Key Metrics

TER 0.57% per year

Distribution policy Distributing

Fund size USD 402 M

Inception date June 23, 2005

Holdings 34

Fund currency USD

Fund domicile US

Provider Invesco

For full official fund details, factsheets, and holdings, visit invesco.com (opens in new tab).

Historical Return

Last updated: Jul 01, 2026

1 Year +46.7% +0.9% Div

3 Years (avg.) +16.2% +0.9% Div

5 Years (avg.) +7.7% +0.9% Div

Risk & Analysis Metrics

Last updated: Jul 01, 2026

Volatility

15.83% 1 Year

15.46% 3 Years

15.95% 5 Years

18.21% 10 Years

Max Drawdown

-9.67% 1 Year

-17.00% 3 Years

-18.74% 5 Years

-35.20% 10 Years

Sharpe Ratio

1.98 1 Year

0.73 3 Years

0.26 5 Years

0.19 10 Years

Return Triangle (Heatmap)

Last updated: Jul 01, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	20.5%	21.0%	30.7%	29.2%	24.0%	15.7%	15.2%	12.5%	11.5%	11.3%	11.5%	10.2%	9.1%	9.0%	10.1%
2012		21.5%	36.1%	32.3%	24.9%	14.8%	14.3%	11.4%	10.4%	10.4%	10.6%	9.3%	8.2%	8.2%	9.4%
2013			52.5%	38.0%	26.0%	13.2%	13.0%	9.8%	8.9%	9.0%	9.5%	8.2%	7.1%	7.2%	8.5%
2014				24.8%	14.5%	2.5%	4.8%	2.8%	2.9%	3.9%	5.1%	4.1%	3.4%	3.8%	5.5%
2015					5.0%	-7.2%	-1.1%	-2.1%	-1.0%	0.8%	2.5%	1.8%	1.2%	1.9%	3.9%
2016						-17.9%	-4.1%	-4.4%	-2.4%	0.0%	2.1%	1.4%	0.8%	1.6%	3.8%
2017							12.1%	3.2%	3.4%	5.0%	6.6%	5.0%	3.8%	4.3%	6.5%
2018								-4.9%	-0.7%	2.8%	5.3%	3.6%	2.4%	3.2%	5.8%
2019									3.6%	6.9%	9.0%	5.9%	4.0%	4.6%	7.5%
2020										10.3%	11.8%	6.6%	4.1%	4.9%	8.1%
2021											13.3%	4.9%	2.1%	3.5%	7.7%
2022												-2.9%	-3.1%	0.5%	6.3%
2023													-3.3%	2.2%	9.6%
2024														8.1%	16.7%
2025															26.0%

Distributions

*by ETF Portfolio Weight Last updated: Jul 01, 2026

Profit Margin Distribution

< 0%

17%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

1y 3y N/A N/A

10 - 15%

24%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

18%

1y 3y N/A N/A

30 - 40%

11%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

17%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

12%

1y 3y N/A N/A

15 - 20

20%

1y 3y N/A N/A

20 - 25

11%

1y 3y N/A N/A

25 - 35

10%

1y 3y N/A N/A

35 - 50

16%

1y 3y N/A N/A

> 50

12%

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

0.0%

1y 3y N/A N/A

Small Cap

14.2%

1y 3y N/A N/A

Mid Cap

26.9%

1y 3y N/A N/A

Large Cap

38.0%

1y 3y N/A N/A

Mega Cap

20.9%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Jun 28, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$137B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	1.43%	2.01%
Beta Indicates the relationship between the price performance of a share and the market.	0.55	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	35.91	28.61
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-85.69	-
Profitable Companies	73%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	807.33	18.04
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	5.27	8.09
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	9.21	10.18

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	25.49	20.33
Enterprise Value to Revenue Enterprise value divided by revenue	69.09	7.98
Total Debt to Enterprise Value Total debt divided by enterprise value	0.19	0.04
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.48	0.27
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	-1218.27%	20.81%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-	-118.0%
Return on Equity Equity divided by market cap.	21.71%	2.67%
Return on Assets Indicates a company's profitability in relation to its total assets.	4.34%	4.17%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	9.85%	3.72%

Sectors

Manufacturing	96.4%
Finance and Insurance	3.5%
Other	0.1%

Countries

United States	94.9%
Ireland	5.1%
Other	0.0%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Gilead Sciences, Inc.

GILD - Manufacturing

Market Cap $158.77B

P/E Ratio 17.2

Dividends 2.5%

Total Investment $22.97M

Weight 5.71%

Loading details…

Johnson & Johnson

JNJ - Manufacturing

Market Cap $613.02B

P/E Ratio 29.4

Dividends 2.1%

Total Investment $22.34M

Weight 5.56%

Loading details…

Merck & Co Inc

MRK - Manufacturing

Market Cap $317.08B

P/E Ratio 36.1

Dividends 2.6%

Total Investment $22.26M

Weight 5.53%

Loading details…

Pfizer Inc.

PFE - Manufacturing

Market Cap $138.41B

P/E Ratio 18.5

Dividends 7.1%

Total Investment $21.25M

Weight 5.28%

Loading details…

AMGEN Inc.

AMGN - Manufacturing

Market Cap $193.39B

P/E Ratio 24.7

Dividends 2.7%

Total Investment $20.74M

Weight 5.16%

Loading details…

Abbvie Inc

ABBV - Manufacturing

Market Cap $444.38B

P/E Ratio 123.3

Dividends 2.7%

Total Investment $19.69M

Weight 4.90%

Loading details…

Lilly(Eli) & Co

LLY - Manufacturing

Market Cap $1.14T

P/E Ratio 42.8

Dividends 0.5%

Total Investment $19.68M

Weight 4.89%

Loading details…

Abbott Laboratories

ABT - Manufacturing

Market Cap $163.42B

P/E Ratio 26.1

Dividends 2.6%

Total Investment $17.42M

Weight 4.33%

Loading details…

Liquidia Corp

LQDA - Manufacturing

Market Cap $6.95B

P/E Ratio 326.9

Dividends 0.0%

Total Investment $15.93M

Weight 3.96%

Loading details…

Viatris Inc

VTRS - Finance and Insurance

Market Cap $19.02B

P/E Ratio -61.9

Dividends 2.9%

Total Investment $13.9M

Weight 3.46%

Loading details…

Bristol-Myers Squibb Co.

BMY - Manufacturing

Market Cap $117.46B

P/E Ratio 16.2

Dividends 4.3%

Total Investment $12.94M

Weight 3.22%

Loading details…

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

AMRX - Manufacturing

Market Cap $5.5B

P/E Ratio 45.5

Dividends 0.0%

Total Investment $12.64M

Weight 3.14%

Loading details…

Prestige Consumer Healthcare Inc

PBH - Manufacturing

Market Cap $2.34B

P/E Ratio 12.5

Dividends 0.0%

Total Investment $12.59M

Weight 3.13%

Loading details…

Perrigo Company plc

PRGO - Manufacturing

Market Cap $1.38B

P/E Ratio -0.8

Dividends 11.7%

Total Investment $12.56M

Weight 3.12%

Loading details…

Supernus Pharmaceuticals Inc

SUPN - Manufacturing

Market Cap $2.72B

P/E Ratio -91.6

Dividends 0.0%

Total Investment $11.97M

Weight 2.98%

Loading details…

Harmony Biosciences Holdings Inc

HRMY - Manufacturing

Market Cap $2.05B

P/E Ratio 14.1

Dividends 0.0%

Total Investment $11.62M

Weight 2.89%

Loading details…

Biogen Inc

BIIB - Manufacturing

Market Cap $31.89B

P/E Ratio 23.1

Dividends 0.0%

Total Investment $11.42M

Weight 2.84%

Loading details…

ANI Pharmaceuticals Inc

ANIP - Manufacturing

Market Cap $1.92B

P/E Ratio 20.6

Dividends 0.0%

Total Investment $11.35M

Weight 2.82%

Loading details…

Collegium Pharmaceutical Inc

COLL - Manufacturing

Market Cap $1.19B

P/E Ratio 15.4

Dividends 0.0%

Total Investment $11.31M

Weight 2.81%

Loading details…

Amphastar Pharmaceuticals Inc

AMPH - Manufacturing

Market Cap $960.34M

P/E Ratio 12.7

Dividends 0.0%

Total Investment $11.13M

Weight 2.77%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.

This ‘Dividend’ ETF Pays Just 1.2% | So Why Do Serious Investors Keep Buying It?

The Portfolio That Could Put You in a New Car Every Year for Life

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Gilead Sciences, Inc.

Gilead Sciences, Inc.

Johnson & Johnson

Johnson & Johnson

Merck & Co Inc

Merck & Co Inc

Pfizer Inc.

Pfizer Inc.

AMGEN Inc.

AMGEN Inc.

Abbvie Inc

Abbvie Inc

Lilly(Eli) & Co

Lilly(Eli) & Co

Abbott Laboratories

Abbott Laboratories

Liquidia Corp

Liquidia Corp

Viatris Inc

Viatris Inc

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc

Perrigo Company plc

Perrigo Company plc

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Biogen Inc

Biogen Inc

ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Cookie Settings